All In Biotech

Drug Trial Radar · NCT03662126

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 385 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

385

Planned (sponsor's estimate)

Start

Jan 15, 2019

Primary completion

Dec 31, 2023

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to "cross-over" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time.

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-Polycythemia Vera MF (Post-PV-MF)
  • Post-Essential Thrombocythemia MF (Post-ET-MF)

Interventions

  • KRT-232Drug

    KRT-232, administered by mouth

  • Best Available Therapy (BAT)Drug

    Best available therapy options include: 1. hydroxyurea 2. chemotherapy or 3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Part A Only) Spleen Volume Reduction (SVR)Time frame: 24 weeks
  2. (Part B Only) Spleen Volume Reduction (SVR)Time frame: 24 Weeks

Locations

191 sites in 28 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama · Active not recruiting

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • Stanford Cancer Center - Palo Alto

    Stanford, California · Active not recruiting

  • Innovative Clinical Research Institute

    Whittier, California · Completed

  • University Cancer Institute

    Boynton Beach, Florida · Withdrawn

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois · Completed

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Withdrawn

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Brookdale University Hospital and Medical Center

    Brooklyn, New York · Recruiting

  • New York Presbyterian/Weill Cornell Medical Center

    New York, New York · Withdrawn

  • Mt. Sinai

    New York, New York · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Completed

  • Oregon Health and Science University

    Portland, Oregon · Completed

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Medical College of Wisconsin - Froedtert Hospital

    Milwaukee, Wisconsin · Recruiting

  • Instituto Medico Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Centro Medico San Luis

    CABA, Argentina · Recruiting

  • Hospital Privado - Centro Medico de Cordoba - Oncology

    Córdoba, Argentina · Recruiting

  • Sanatorio de la Mujer

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Australia · Recruiting

  • South Eastern Private Hospital

    Noble Park, Australia · Recruiting

  • Icon Cancer Center

    South Brisbane, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Recruiting

  • Fiona Stanley Hosital

    Murdoch, Western Australia, Australia · Recruiting

  • Hospital das Clínicas UFG

    Goiânia, Brazil · Recruiting

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica

    Porto Alegre, Brazil · Recruiting

  • Associação Educadora São Carlos AESC - Hospital Mãe de Deus - Centro de Pesquisa

    Porto Alegre, Brazil · Recruiting

  • Instituto de Ensino e Pesquisa São Lucas

    São Paulo, Brazil · Recruiting

  • Hospital A C Camargo - Fundacao Antonio Prudente

    São Paulo, Brazil · Recruiting

  • Instituto D'or de Pesquisa e Ensino

    São Paulo, Brazil · Recruiting

  • Hospital das Clínicas da Universidade de São Paulo

    São Paulo, Brazil · Recruiting

  • Instituto COI São Paulo

    São Paulo, Brazil · Recruiting

  • Centro de oncologia Leonardo da Vinci

    Fortaleza, Ceará, Brazil · Recruiting

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil · Recruiting

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.